Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: A meta-analysis of 23 randomized lipid trials

Current Opinion in Lipidology

Volumn 17, Issue 6, 2006, Pages 631-636

  Brown, B Greg ^a,c   Stukovsky, Karen Hinckley ^b   Zhao, Xue Qiao ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Atherosclerosis; Clinical trials; Fibrates; Niacin; Statins

Indexed keywords

COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

ALGORITHM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DRUG CLASSIFICATION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHESIS; ISCHEMIC HEART DISEASE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; HUMANS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33750897238     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32800ff750     Document Type: Review

References (21)

1. Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy. The Framingham Offspring Study. Am J Med 1991; 90:11-16.
2. Assman G, Cullen P, Schulte H. The Munster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J 1998; 19 (Suppl A):A2-A11.
3. LaRosa JC, He J, Vupputuri S, et al. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282:2340-2346.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360:7-22.
5. Gordon DJ, Probstfield JL, Garrison RJ, et al. High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79:8-15.
6. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298.
7. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993; 88:2762-2770.
8. Brown BG, Gotto AM. Impact of management on stabilization of plaque and reduction of cardiovascular events. In: Fuster V, Topol EJ, Nabel EG, editors. Atherothrombosis and coronary artery disease. Lippincott Williams & Wilkins: Philadelphia, 2005; pp. 153-164. A summary of arteriographic trials to 1999.
9. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999; 341:410-418.
10. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001; 357: 905-910.
11. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005; 142:95-104. Demonstrates striking clinical and arteriographic benefits from a nonstatin, HDL-focused, drug regimen.
12. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 366: 1849-1861. A disappointing result, confounded by greater statin drop-in in the placebo group.
13. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-381.
14. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and coronary atherosclerosis study [LCAS]). Am J Cardiol 1997; 80:278-286.
15. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
16. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The TNT study. N Engl J Med 2005; 352:1425-1435.
17. Pedersen TR, Faergeman O, Kastelein JJP, et al. High dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445.
18. Sever PS, Poulter NR, Dahlhof B, et al. Reduction of cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes. Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care 2005; 28:1151-1157.
19. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.
20. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257:3233-3240.
21. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322:1700-1707.